<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40617605</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Coronary atherosclerosis screening in asymptomatic adults using coronary artery calcium for cardiovascular prevention: a systematic review of randomised controlled trials and prospective cohorts.</ArticleTitle><Pagination><StartPage>e101472</StartPage><MedlinePgn>e101472</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e101472</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2025-101472</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To review the available evidence of screening for atherosclerosis in adults in a primary prevention setting with coronary artery calcium scoring (CACS) on the impact on cardiovascular (CV) risk factor control, health behaviour and clinical events.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Systematic review, reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">We searched MEDLINE, Embase and Cochrane Central Register of Controlled Trials through 22 January 2025.</AbstractText><AbstractText Label="ELIGIBILITY CRITERIA" NlmCategory="METHODS">We included randomised controlled trials (RCTs) and prospective cohorts, without language restrictions, comparing adults without cardiovascular diseases undergoing CACS to a control group that either did not undergo CACS or where the participants and physicians were blinded to its result. Outcomes included changes in CV risk factor control, CV therapy, changes in health behaviour at follow-up and clinical events (all-cause and CV mortality and non-fatal CV events).</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="METHODS">Two independent reviewers extracted data and assessed the risk of bias. Due to substantial heterogeneity among the included studies, a quantitative analysis was not possible.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified seven RCTs and one observational study, with participants ranging from 56 to 43&#x2009;447 with a total of 51&#x2009;554. Populations were heterogeneous with a mean age range of 42-64 years, % women ranging from 21% to 100%&#x2009;and mean baseline CACS from 1.37 to &gt;100 Agatston units. Interventions following CACS were also heterogeneous, ranging from simply communicating results to participants to initiating statin therapy for detectable CACS. One RCT demonstrated improvement regarding blood pressure (BP) (n=2137; change in systolic BP: CACS: -5&#x2009;mm Hg; control: -7&#x2009;mm Hg; p=0.02), several an improvement in blood lipids between groups (five studies, n=3693; eg, low-density lipoprotein (LDL) cholesterol: range -6.0 to -4.9 mg/dL). Results regarding CV medication (seven studies, n=51&#x2009;104) were more discrepant, with some studies showing a decrease and others an increase in indication for or usage of CV medication. Three trials (n=3338) investigated adherence to CV medication, with only one showing increased adherence to statins (CACS: 63.3%; control: 45.6%; p=0.03). Five trials (n=3692) investigated behavioural changes, with one showing an increased motivation to change lifestyle (CACS: 94%; control: 62.8%; p=0.002) and another a higher adherence in self-reported physical activity (CACS: 96%; control: 59%; p&lt;0.01). Due to low event rates, short follow-up and/or limited sample size, none (three studies, n=6552) demonstrated an effect on clinical CV events or all-cause mortality. Heterogeneity in interventions following CACS, population and studied outcomes did not permit pooling of results. Key limitations of this review reflect the limited availability of evidence and include the omission of potential harms of CACS screening, study heterogeneity, insufficient data on clinical events, a lack of economic assessments and the moderate to high risk of bias in most studies.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CACS screening with a CACS-guided intervention might have a favourable effect on CV risk factor control and potentially on adherence to CV medication and increased motivation to change lifestyle in populations at intermediate to high risk. The available evidence is insufficient to determine whether screening asymptomatic patients with CACS has an impact on all-cause mortality or CV events. Despite its known strengths in predicting outcomes in individual patients, more evidence regarding the impact on clinical outcomes is needed to determine the clinical use of CACS for screening purposes in asymptomatic patients.</AbstractText><AbstractText Label="PROSPERO REGISTRATION NUMBER" NlmCategory="UNASSIGNED">CRD42022377727.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheu</LastName><ForeName>Victor</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-8605-977X</Identifier><AffiliationInfo><Affiliation>Department of General Internal Medicine, Inselspital University Hospital Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwan</LastName><ForeName>Louhai</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Inselspital University Hospital Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xe4;ni</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Inselspital University Hospital Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gencer</LastName><ForeName>Baris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Cardiology, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodondi</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Inselspital University Hospital Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Manuel R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Inselspital University Hospital Bern, Bern, Switzerland manuel.blum@spitalfmi.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Hospitals Frutigen Meiringen Interlaken, Interlaken, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="Y">Coronary Vessels</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="Y">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061205" MajorTopicYN="Y">Vascular Calcification</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Computed tomography</Keyword><Keyword MajorTopicYN="N">Coronary heart disease</Keyword><Keyword MajorTopicYN="N">Primary Prevention</Keyword><Keyword MajorTopicYN="N">Systematic Review</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>5</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40617605</ArticleId><ArticleId IdType="pmc">PMC12228433</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2025-101472</ArticleId><ArticleId IdType="pii">bmjopen-2025-101472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lindstrom M, Decleene N, Dorsey H, et al. Summary of Global Burden of Disease Study Methods. J Am Coll Cardiol. 2022;80:2372&#x2013;425. doi: 10.1016/j.jacc.2022.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.11.001</ArticleId><ArticleId IdType="pubmed">36517116</ArticleId></ArticleIdList></Reference><Reference><Citation>Eagle KA, Ginsburg GS, Musunuru K, et al. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation . 2010;121:1447&#x2013;54. doi: 10.1161/CIRCULATIONAHA.109.904029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.904029</ArticleId><ArticleId IdType="pmc">PMC2905873</ArticleId><ArticleId IdType="pubmed">20351302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framingham risk score are now much clearer. Prev Med. 2009;48:115&#x2013;6. doi: 10.1016/j.ypmed.2008.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2008.12.002</ArticleId><ArticleId IdType="pubmed">19124038</ArticleId></ArticleIdList></Reference><Reference><Citation>Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227&#x2013;337. doi: 10.1093/eurheartj/ehab484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab484</ArticleId><ArticleId IdType="pubmed">34458905</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596&#x2013;646. doi: 10.1161/CIR.0000000000000678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000678</ArticleId><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: the Multi-Ethnic Study of Atherosclerosis (MESA) Circulation. 2016;133:849&#x2013;58. doi: 10.1161/CIRCULATIONAHA.115.018524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.018524</ArticleId><ArticleId IdType="pmc">PMC4775391</ArticleId><ArticleId IdType="pubmed">26801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeboah J, Young R, McClelland RL, et al. Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment. J Am Coll Cardiol. 2016;67:139&#x2013;47. doi: 10.1016/j.jacc.2015.10.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.10.058</ArticleId><ArticleId IdType="pmc">PMC4724058</ArticleId><ArticleId IdType="pubmed">26791059</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285&#x2013;350. doi: 10.1016/j.jacc.2018.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.003</ArticleId><ArticleId IdType="pubmed">30423393</ArticleId></ArticleIdList></Reference><Reference><Citation>McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study) J Am Coll Cardiol. 2015;66:1643&#x2013;53. doi: 10.1016/j.jacc.2015.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.08.035</ArticleId><ArticleId IdType="pmc">PMC4603537</ArticleId><ArticleId IdType="pubmed">26449133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadamitzky M, Achenbach S, Al-Mallah M, et al. Optimized prognostic score for coronary computed tomographic angiography: results from the CONFIRM registry (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter Registry) J Am Coll Cardiol. 2013;62:468&#x2013;76. doi: 10.1016/j.jacc.2013.04.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.04.064</ArticleId><ArticleId IdType="pubmed">23727215</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzaye O, Berning P, Adelhoefer S, et al. Temporal Trends and Interest in Coronary Artery Calcium Scoring Over Time: An Infodemiology Study. Mayo Clin Proc Innov Qual Outcomes. 2021;5:456&#x2013;65. doi: 10.1016/J.MAYOCPIQO.2021.02.010/ATTACHMENT/AEA37B01-DF6B-49BE-85FA-FA82F07325D8/MMC1.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MAYOCPIQO.2021.02.010/ATTACHMENT/AEA37B01-DF6B-49BE-85FA-FA82F07325D8/MMC1.PDF</ArticleId><ArticleId IdType="pmc">PMC8105517</ArticleId><ArticleId IdType="pubmed">33997641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer MS. Elements of danger--the case of medical imaging. N Engl J Med. 2009;361:841&#x2013;3. doi: 10.1056/NEJMp0904735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp0904735</ArticleId><ArticleId IdType="pubmed">19710480</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RP, Sheridan SL, Lewis CL, et al. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014;174:281&#x2013;5. doi: 10.1001/jamainternmed.2013.12745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.12745</ArticleId><ArticleId IdType="pubmed">24322781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodondi N, Auer R, de Bosset Sulzer V, et al. Atherosclerosis screening by noninvasive imaging for cardiovascular prevention: a systematic review. J Gen Intern Med. 2012;27:220&#x2013;31. doi: 10.1007/s11606-011-1833-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-011-1833-3</ArticleId><ArticleId IdType="pmc">PMC3270245</ArticleId><ArticleId IdType="pubmed">21882076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamudu HM, Paul TK, Veeranki SP, et al. The effects of coronary artery calcium screening on behavioral modification, risk perception, and medication adherence among asymptomatic adults: a systematic review. Atherosclerosis. 2014;236:338&#x2013;50. doi: 10.1016/j.atherosclerosis.2014.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2014.07.022</ArticleId><ArticleId IdType="pubmed">25128971</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KJL, White S, Hassan O, et al. Evaluation of the Incremental Value of a Coronary Artery Calcium Score Beyond Traditional Cardiovascular Risk Assessment: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022;182:634&#x2013;42. doi: 10.1001/jamainternmed.2022.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.1262</ArticleId><ArticleId IdType="pmc">PMC9039826</ArticleId><ArticleId IdType="pubmed">35467692</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry SJ, Krist AH, Owens DK, et al. Risk assessment for cardiovascular disease with nontraditional risk factors: US preventive services task force recommendation statement. JAMA. 2018;320:272&#x2013;80. doi: 10.1001/jama.2018.8359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.8359</ArticleId><ArticleId IdType="pubmed">29998297</ArticleId></ArticleIdList></Reference><Reference><Citation>Borissov N, Haas Q, Minder B, et al. Reducing systematic review burden using Deduklick: a novel, automated, reliable, and explainable deduplication algorithm to foster medical research. Syst Rev. 2022;11:1&#x2013;10. doi: 10.1186/S13643-022-02045-9/FIGURES/2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13643-022-02045-9/FIGURES/2</ArticleId><ArticleId IdType="pmc">PMC9382798</ArticleId><ArticleId IdType="pubmed">35978441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Collaboration RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias. Br Med J. 2022:1&#x2013;24.</Citation></Reference><Reference><Citation>Ottawa Hospital Research Institute. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Available.</Citation></Reference><Reference><Citation>Denissen SJ, van der Aalst CM, Vonder M, et al. Impact of a cardiovascular disease risk screening result on preventive behaviour in asymptomatic participants of the ROBINSCA trial. Eur J Prev Cardiol. 2019;26:1313&#x2013;22. doi: 10.1177/2047487319843396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487319843396</ArticleId><ArticleId IdType="pubmed">30966821</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Malley PG, Feuerstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. JAMA. 2003;289:2215&#x2013;23. doi: 10.1001/jama.289.17.2215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.17.2215</ArticleId><ArticleId IdType="pubmed">12734132</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhlestein JB, Knowlton KU, Le VT, et al. Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. JACC Cardiovasc Imaging. 2022;15:843&#x2013;55. doi: 10.1016/j.jcmg.2021.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2021.11.006</ArticleId><ArticleId IdType="pubmed">34922872</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Aalst CM, Denissen SJAM, Vonder M, et al. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. Eur Heart J Cardiovasc Imaging. 2020;21:1216&#x2013;24. doi: 10.1093/ehjci/jeaa168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jeaa168</ArticleId><ArticleId IdType="pubmed">32584979</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmore K, Zhou Z, Ryan JDM, et al. Influence of repeated plaque visualization on cardiovascular risk reduction after 3 years: a randomized controlled trial. Eur J Prev Cardiol. 2025;32:596&#x2013;605. doi: 10.1093/eurjpc/zwae026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwae026</ArticleId><ArticleId IdType="pubmed">38243798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57:1622&#x2013;32. doi: 10.1016/j.jacc.2011.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.01.019</ArticleId><ArticleId IdType="pmc">PMC3104928</ArticleId><ArticleId IdType="pubmed">21439754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederman J, Ballard J, Njike VY, et al. Information given to postmenopausal women on coronary computed tomography may influence cardiac risk reduction efforts. J Clin Epidemiol. 2007;60:389&#x2013;96. doi: 10.1016/j.jclinepi.2006.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2006.07.010</ArticleId><ArticleId IdType="pubmed">17346614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi WC, Sylwestrzak G, Barron J, et al. Does CAC testing alter downstream treatment patterns for cardiovascular disease? Am J Manag Care. 2014;20:e330&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25295796</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodondi N, Collet T-H, Nanchen D, et al. Impact of carotid plaque screening on smoking cessation and other cardiovascular risk factors: a randomized controlled trial. Arch Intern Med. 2012;172:344&#x2013;52. doi: 10.1001/archinternmed.2011.1326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2011.1326</ArticleId><ArticleId IdType="pubmed">22269590</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschner S, Wing-Lun E, Chow C, et al. Randomised clinical trial using Coronary Artery Calcium Scoring in Australian Women with Novel Cardiovascular Risk Factors (CAC-WOMEN Trial): study protocol. BMJ Open. 2022;12:e062685. doi: 10.1136/bmjopen-2022-062685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062685</ArticleId><ArticleId IdType="pmc">PMC9772643</ArticleId><ArticleId IdType="pubmed">36549726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosius WT, Polonsky TS, Greenland P, et al. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials . 2012;9:232&#x2013;46. doi: 10.1177/1740774512436882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774512436882</ArticleId><ArticleId IdType="pmc">PMC4475283</ArticleId><ArticleId IdType="pubmed">22333998</ArticleId></ArticleIdList></Reference><Reference><Citation>Diederichsen ACP, Rasmussen LM, S&#xf8;gaard R, et al. The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial. Trials. 2015;16:554. doi: 10.1186/s13063-015-1082-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-015-1082-6</ArticleId><ArticleId IdType="pmc">PMC4670524</ArticleId><ArticleId IdType="pubmed">26637993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholt JS, S&#xf8;gaard R, Rasmussen LM, et al. Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med . 2022;387:1385&#x2013;94. doi: 10.1056/NEJMoa2208681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208681</ArticleId><ArticleId IdType="pubmed">36027560</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott M, Meah MN, Khaing P, et al. Rationale and Design of SCOT-HEART 2 Trial: CT Angiography for the Prevention of Myocardial Infarction. JACC Cardiovasc Imaging. 2024;17:1101&#x2013;12. doi: 10.1016/j.jcmg.2024.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2024.05.016</ArticleId><ArticleId IdType="pubmed">39001735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>